Investigational drug · Phase 2
AST-301
Also called: pNGVL3-hICD
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Gastric Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "AST-301"
First trial start
2023
Jul 4, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AST-301", any sponsor or status.
Conditions studied
As listed on its trial records.
- Gastric Cancer
Approved drugs for the same conditions: Stomach and esophageal cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "AST-301" as an intervention, largest first.
- Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian CancerNot yet recruiting
Aston Sci. Inc.Industry
NCT05794659 · 98 participants (planned) · Start Jun 1, 2027 · Primary completion Dec 31, 2030
Drug: AST-201; Paclitaxel and 3 more · For: Advanced Ovarian Cancer
Sites: Seattle, Washington
- Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Gastric CancerActive, not recruiting
Aston Sci. Inc.Industry
NCT05771584 · 24 participants · Start Jul 4, 2023 · Primary completion Feb 9, 2027
Drug: AST-301; rhuGM-CSF · For: Gastric Cancer
Sites: Kaohsiung City, Taiwan; Taichung, Taiwan; Tainan, Taiwan · 6 sites in all
Aston Sci. Inc.Industry
NCT05163223 · 10 participants · Start Feb 28, 2022 · Primary completion May 31, 2024
Drug: AST-301(pNGVL3-hICD); rhuGM-CSF and 3 more · For: Breast Cancer
Sites: Chandler, Arizona; La Jolla, California; Tampa, Florida · 17 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Gastric Cancer
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- ApatinibRIVO, RivoceranibPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · Gastric Cancer, HCC, Hepatocellular Carcinoma
- CamrelizumabSHR-1210, CAMPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- PD-1 monoclonal antibodyPhase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
- Tegafur-gimeracil-oteracil potassiumS-1, tegafurPhase 38 trials
Ono Pharmaceutical Co., Ltd. · Gastric Cancer, Esophageal Cancer, Resectable Gastric/Gastroesophageal Junction Adenocarcinoma
- AZD0901Sonesitatug vedotin, CMG901Phase 36 trials
AstraZeneca · Gastric Cancer, Gastroesophageal Junction Cancer, Gastroesophageal Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.